Summary
Objective - Dilated cardiomyopathy is a rare disorder in childhood that results in a high mortality. The aim of our study was to evaluate the prognostic relevance of the individual plasma carnitine status in children with dilated cardiomyopathy.
Methods - In 26 patients plasma carnitine concentrations were determined before and after 6 and 12 months of L-carnitine treatment. According to the plasma short chain acyl-carnitine/free carnitine ratio (AC/FC) at the first presentation children were divided into two groups.
Results - In group 1 (AC/FC < 0.4) the median time from diagnosis until death was 35.8 months, the cumulative survival rate was 84% after 2 years. In group 2 (AC/FC > 0.4) median time from diagnosis until death was 8 months, the cumulative survival rate was 50% at 2 years (p < 0.05).
Dividing both groups into survivors and nonsurvivors in group 2 a significantly higher AC/FC ratio in the nonsurvivors could be found (survivors 0.78 v 1.3 in nonsurvivors). A significant improvement of left ventricular function 6 and 12 months after presentation and after starting L-carnitine treatment could only be documented in the surviving patients of group 2.
Conclusion - The individual plasma carnitine status in children with dilated cardiomyopathy may serve as a risk factor for survival.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Akagi T, Benson LN, Lightfoot NE, Chin K, Wilson G, Freedom RM (1991) Natural history of dilated cardiomyopathy in children. Am Heart J 121: 1502–1506
Battistella A, Vergani L, Donzelli F, Rubaltelli FF, Angelini C (1980) Plasma and urine carnitine levels during development. Pediat Res 14: 1379–1381
Berko BA, Swift M (1987) X-linked dilated cardiomyopathy. N Engl J Med 316: 1186–1189
Bohles H, Evangeliou A, Bervoets K (1994) Carnitine esters in metabolic disease. Eur J Pediatr 153 [Suppl] 1: 57–61
Brass EP, Hoppel CL (1980) Relationship between acid-soluble carnitine and coenzyme A pools in vivo. Biochem J 190: 459
Cederblad G, Linstedt S (1972) A method for the determination of carnitine in the picomole range. Clin Chem Acta 37: 235–240
Chen SC, Nouri S, Balfour I, Jureidini S, Appleton S (1990) Clinical profile of congestive cardiomyopathy in children. J Am Coll Cardiol 15: 189–193
Ciszewski A, Bilinska ZT, Lubiszewska B, Ksiezycka E, Poplawska W, Michalak E, Walczak E, Walczak F, Ruzyllo W (1994) Dilated cardiomyopathy in children: clinical course and prognosis. Pediatr Cardiol 15: 121–126
Drexler H (1992) Skeletal muscle failure in heart failure. Circulation 85: 1621–1623
Engel AG (1980) Possible causes and effects of carnitine deficiency in man. In: Frankel RA, McGarry D (eds) Carnitine biosynthesis, metabolism and function. Academic Press, New York, pp 271–285
Engel AG, Angelini C (1973) Carnitine deficiency of human skeletal muscle with associated lipid storage myopathy: a new syndrome. Science 179: 899–902
Feigenbaum H (1986) Echocardiography. Perimed, Erlangen, pp 148–151
Friedman RA, Moak JP, Garson A Jr (1991) Clinical course of idiopathic dilated cardiomyopathy in children. J Am Coll Cardiol 18: 152–156
Fuster V, Gersh BJ, Giccliani ER, Tajik AJ, Brandenberg RO, Frye RL (1981) The natural history of idiopathic dilated cardiomyopathy. Am J Cardiol 47: 525–531
Greenwood M (1926) The errors of sampling of the survivorship tables: Appendix 1. In: Reports on Puplic Health and Statistical Subects. no 33. London: His Majesty's Stationary Office
Griffin ML, Hernandez A, Martin ThC, Goldring D, Bolman RM, Spray ThL, Strauss AW (1988) Dilated cardiomyopathy in infants and children. J Am Coll Cardiol 11: 139–144
Hütter JF, Piper HM, Spieckermann PG (1985) Effect of fatty acid oxidation on efficiency of energy production in rat hearts. Am J Physiol 249: 723–728
Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481
Lewis AB, Chabot M (1991) Outcome of infants and children with dilated cardiomyopathy. Am J Cardiol 68: 365–369
Lohninger A, Kaiser E, Legenstein E, Staniek H (1987) Carnitine, metabolism and function. In: Kaiser E, Lohninger A (eds) Carnitine - Its role in lung and heart disorders. Karger, Basel, pp 1–25
Magnusson G, Isberg B, Karlberg KE, Sylven C (1994) Skeletal muscle strength and endurance in chronic congestive heart failure secondary to idiopathic dilated cardiomyopathy. Am J Cardiol 73: 307–309
Mancini DM, Wilson JR, Bolinger L, Li H, Kendrick K, Chance B, Leigh JS (1994) In vivo magnetic resonance spectroscopy measurement of deoxymyoglobin during exercise in patients with heart failure: demonstration of abnormal muscle metabolism despite adequate oxygenation. Circulation 90: 500–508
Opie LH (1979) Role of carnitine in fatty acid metabolism of normal and ischemic myocardium. Am Heart J 97: 375–378
SAS User's Guide (1985) Statistics. Version 5 Edition: SAS Institute Inc. Cary, NC
Shug AL (1975) Acyl-CoA inhibition of adenine nucleotide translocase in ischemic myocardium. Am J Physiol 228: 689–692
Tripp ME, Shug AL (1984) Plasma carnitine concentrations in cardiomyopathy patients. Biochem Med 32: 199–206
Winter SC, Szabo-Aczel S, Curry CJR, et al. (1987) Plasma carnitine deficiency: clinical observations in 51 patients. AJDC 141: 660–665
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Marx, M., Skyllouriotis, M., Legenstein, E. et al. Plasma carnitine status - a prognostic factor in children with dilated cardiomyopathy. Amino Acids 12, 157–166 (1997). https://doi.org/10.1007/BF01386478
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01386478